[TITLE]Quantbot Technologies LP Invests $554,000 in Healthcare Services Group, Inc. $HCSG:
[TEXT]
Quantbot Technologies LP bought a new position in Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 54,967 shares of the business services provider’s stock, valued at approximately $554,000. Quantbot Technologies LP owned approximately 0.08% of Healthcare Services Group at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of HCSG. US Bancorp DE lifted its holdings in Healthcare Services Group by 161.4% during the 1st quarter. US Bancorp DE now owns 8,097 shares of the business services provider’s stock worth $82,000 after buying an additional 5,000 shares in the last quarter. PharVision Advisers LLC acquired a new position in Healthcare Services Group during the 4th quarter worth $147,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Healthcare Services Group by 45.3% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,592 shares of the business services provider’s stock worth $147,000 after buying an additional 4,548 shares in the last quarter. Dark Forest Capital Management LP acquired a new position in Healthcare Services Group during the 4th quarter worth $158,000. Finally, MQS Management LLC acquired a new position in Healthcare Services Group during the 1st quarter worth $173,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

Get Healthcare Services Group alerts:

Wall Street Analysts Forecast Growth

HCSG has been the topic of several research reports. Macquarie raised Healthcare Services Group from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, July 29th. Benchmark upped their price objective on Healthcare Services Group from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Wall Street Zen cut shares of Healthcare Services Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 26th. Robert W. Baird upped their target price on shares of Healthcare Services Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Finally, Zacks Research upgraded shares of Healthcare Services Group to a “strong-buy” rating in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Healthcare Services Group has an average rating of “Buy” and a consensus target price of $16.25.

Insider Buying and Selling

In related news, EVP John Christopher Shea sold 21,368 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $13.25, for a total transaction of $283,126.00. Following the sale, the executive vice president owned 32,976 shares of the company’s stock, valued at approximately $436,932. This trade represents a 39.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.10% of the company’s stock.

Healthcare Services Group Trading Down 1.8%

Shares of Healthcare Services Group stock opened at $15.49 on Tuesday. The company has a market capitalization of $1.12 billion, a PE ratio of 110.64 and a beta of 0.54. Healthcare Services Group, Inc. has a 12 month low of $9.13 and a 12 month high of $15.89. The stock’s fifty day simple moving average is $14.29 and its 200 day simple moving average is $12.81.

Healthcare Services Group (NASDAQ:HCSG – Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The business services provider reported $0.21 EPS for the quarter, topping the consensus estimate of $0.20 by $0.01. The business had revenue of $458.50 million for the quarter, compared to the consensus estimate of $450.78 million. Healthcare Services Group had a return on equity of 11.74% and a net margin of 0.61%.The firm’s revenue was up 7.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 EPS. Healthcare Services Group has set its Q3 2025 guidance at EPS. Analysts predict that Healthcare Services Group, Inc. will post 0.74 EPS for the current fiscal year.
[Source link]: https://www.etfdailynews.com/2025/08/26/quantbot-technologies-lp-invests-554000-in-healthcare-services-group-inc-hcsg/


[TITLE]Invesco Ltd. Trims Stake in AMN Healthcare Services Inc $AMN:
[TEXT]
Invesco Ltd. lowered its stake in AMN Healthcare Services Inc (NYSE:AMN – Free Report) by 10.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 348,521 shares of the company’s stock after selling 40,043 shares during the quarter. Invesco Ltd.’s holdings in AMN Healthcare Services were worth $8,525,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMN. Golden State Wealth Management LLC lifted its stake in AMN Healthcare Services by 107.0% in the 1st quarter. Golden State Wealth Management LLC now owns 1,159 shares of the company’s stock valued at $28,000 after buying an additional 599 shares in the last quarter. LRI Investments LLC lifted its stake in AMN Healthcare Services by 368.2% in the 4th quarter. LRI Investments LLC now owns 1,620 shares of the company’s stock valued at $39,000 after buying an additional 1,274 shares in the last quarter. Covestor Ltd lifted its stake in AMN Healthcare Services by 59.6% in the 1st quarter. Covestor Ltd now owns 4,650 shares of the company’s stock valued at $114,000 after buying an additional 1,736 shares in the last quarter. GAMMA Investing LLC lifted its stake in AMN Healthcare Services by 74.9% in the 1st quarter. GAMMA Investing LLC now owns 5,278 shares of the company’s stock valued at $129,000 after buying an additional 2,260 shares in the last quarter. Finally, NBC Securities Inc. lifted its stake in AMN Healthcare Services by 109,000.0% in the 1st quarter. NBC Securities Inc. now owns 5,455 shares of the company’s stock valued at $133,000 after buying an additional 5,450 shares in the last quarter. Hedge funds and other institutional investors own 99.23% of the company’s stock.

Get AMN Healthcare Services alerts:

Analyst Ratings Changes

A number of research analysts have weighed in on AMN shares. BMO Capital Markets reduced their price target on AMN Healthcare Services from $27.00 to $22.00 and set an “outperform” rating on the stock in a research note on Monday, August 11th. JMP Securities reduced their price target on AMN Healthcare Services from $33.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. Finally, UBS Group reduced their price target on AMN Healthcare Services from $30.00 to $25.50 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.25.

AMN Healthcare Services Trading Down 0.3%

AMN stock opened at $20.69 on Tuesday. The company has a market cap of $792.84 million, a price-to-earnings ratio of -2.66 and a beta of 0.10. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.51. The business has a fifty day simple moving average of $20.03 and a 200-day simple moving average of $21.51. AMN Healthcare Services Inc has a 52 week low of $14.86 and a 52 week high of $54.01.

AMN Healthcare Services (NYSE:AMN – Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.13. The business had revenue of $658.18 million during the quarter, compared to the consensus estimate of $652.89 million. AMN Healthcare Services had a positive return on equity of 11.09% and a negative net margin of 10.75%.The business’s revenue for the quarter was down 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.98 EPS. AMN Healthcare Services has set its Q3 2025 guidance at EPS. On average, equities research analysts expect that AMN Healthcare Services Inc will post 1.33 EPS for the current year.

AMN Healthcare Services Profile

(Free Report)

AMN Healthcare Services, Inc provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions.

Read More

Want to see what other hedge funds are holding AMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMN Healthcare Services Inc (NYSE:AMN – Free Report).

Receive News & Ratings for AMN Healthcare Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMN Healthcare Services and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/26/invesco-ltd-trims-stake-in-amn-healthcare-services-inc-amn/


[TITLE]Brooklyn Investment Group Purchases 209 Shares of Tenet Healthcare Corporation $THC:
[TEXT]
Brooklyn Investment Group lifted its position in shares of Tenet Healthcare Corporation (NYSE:THC – Free Report) by 908.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 232 shares of the company’s stock after acquiring an additional 209 shares during the quarter. Brooklyn Investment Group’s holdings in Tenet Healthcare were worth $31,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in THC. Nuveen LLC bought a new position in Tenet Healthcare in the 1st quarter worth
[Source link]: https://www.etfdailynews.com/2025/08/25/brooklyn-investment-group-purchases-209-shares-of-tenet-healthcare-corporation-thc/


[TITLE]American Century Companies Inc. Has $15.32 Million Stake in Cross Country Healthcare, Inc. $CCRN:
[TEXT]
American Century Companies Inc. decreased its holdings in Cross Country Healthcare, Inc. (NASDAQ:CCRN – Free Report) by 0.3% during the first quarter, Holdings Channel.com reports. The firm owned 1,029,028 shares of the business services provider’s stock after selling 3,175 shares during the period. American Century Companies Inc.’s holdings in Cross Country Healthcare were worth $15,322,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Longfellow Investment Management Co. LLC acquired a new position in shares of Cross Country Healthcare in the 1st quarter valued at
[Source link]: https://www.etfdailynews.com/2025/08/25/american-century-companies-inc-has-15-32-million-stake-in-cross-country-healthcare-inc-ccrn/

================================================================================

[TITLE]Quantbot Technologies LP Invests $554,000 in Healthcare Services Group, Inc. $HCSG:
[TEXT]
Quantbot Technologies LP bought a new position in Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 54,967 shares of the business services provider’s stock, valued at approximately $554,000. Quantbot Technologies LP owned approximately 0.08% of Healthcare Services Group at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of HCSG. US Bancorp DE lifted its holdings in Healthcare Services Group by 161.4% during the 1st quarter. US Bancorp DE now owns 8,097 shares of the business services provider’s stock worth $82,000 after buying an additional 5,000 shares in the last quarter. PharVision Advisers LLC acquired a new position in Healthcare Services Group during the 4th quarter worth $147,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Healthcare Services Group by 45.3% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,592 shares of the business services provider’s stock worth $147,000 after buying an additional 4,548 shares in the last quarter. Dark Forest Capital Management LP acquired a new position in Healthcare Services Group during the 4th quarter worth $158,000. Finally, MQS Management LLC acquired a new position in Healthcare Services Group during the 1st quarter worth $173,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

Get Healthcare Services Group alerts:

Wall Street Analysts Forecast Growth

HCSG has been the topic of several research reports. Macquarie raised Healthcare Services Group from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, July 29th. Benchmark upped their price objective on Healthcare Services Group from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Wall Street Zen cut shares of Healthcare Services Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 26th. Robert W. Baird upped their target price on shares of Healthcare Services Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Finally, Zacks Research upgraded shares of Healthcare Services Group to a “strong-buy” rating in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Healthcare Services Group has an average rating of “Buy” and a consensus target price of $16.25.

Insider Buying and Selling

In related news, EVP John Christopher Shea sold 21,368 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $13.25, for a total transaction of $283,126.00. Following the sale, the executive vice president owned 32,976 shares of the company’s stock, valued at approximately $436,932. This trade represents a 39.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.10% of the company’s stock.

Healthcare Services Group Trading Down 1.8%

Shares of Healthcare Services Group stock opened at $15.49 on Tuesday. The company has a market capitalization of $1.12 billion, a PE ratio of 110.64 and a beta of 0.54. Healthcare Services Group, Inc. has a 12 month low of $9.13 and a 12 month high of $15.89. The stock’s fifty day simple moving average is $14.29 and its 200 day simple moving average is $12.81.

Healthcare Services Group (NASDAQ:HCSG – Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The business services provider reported $0.21 EPS for the quarter, topping the consensus estimate of $0.20 by $0.01. The business had revenue of $458.50 million for the quarter, compared to the consensus estimate of $450.78 million. Healthcare Services Group had a return on equity of 11.74% and a net margin of 0.61%.The firm’s revenue was up 7.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 EPS. Healthcare Services Group has set its Q3 2025 guidance at EPS. Analysts predict that Healthcare Services Group, Inc. will post 0.74 EPS for the current fiscal year.
[Source link]: https://www.etfdailynews.com/2025/08/26/quantbot-technologies-lp-invests-554000-in-healthcare-services-group-inc-hcsg/


[TITLE]Invesco Ltd. Trims Stake in AMN Healthcare Services Inc $AMN:
[TEXT]
Invesco Ltd. lowered its stake in AMN Healthcare Services Inc (NYSE:AMN – Free Report) by 10.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 348,521 shares of the company’s stock after selling 40,043 shares during the quarter. Invesco Ltd.’s holdings in AMN Healthcare Services were worth $8,525,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMN. Golden State Wealth Management LLC lifted its stake in AMN Healthcare Services by 107.0% in the 1st quarter. Golden State Wealth Management LLC now owns 1,159 shares of the company’s stock valued at $28,000 after buying an additional 599 shares in the last quarter. LRI Investments LLC lifted its stake in AMN Healthcare Services by 368.2% in the 4th quarter. LRI Investments LLC now owns 1,620 shares of the company’s stock valued at $39,000 after buying an additional 1,274 shares in the last quarter. Covestor Ltd lifted its stake in AMN Healthcare Services by 59.6% in the 1st quarter. Covestor Ltd now owns 4,650 shares of the company’s stock valued at $114,000 after buying an additional 1,736 shares in the last quarter. GAMMA Investing LLC lifted its stake in AMN Healthcare Services by 74.9% in the 1st quarter. GAMMA Investing LLC now owns 5,278 shares of the company’s stock valued at $129,000 after buying an additional 2,260 shares in the last quarter. Finally, NBC Securities Inc. lifted its stake in AMN Healthcare Services by 109,000.0% in the 1st quarter. NBC Securities Inc. now owns 5,455 shares of the company’s stock valued at $133,000 after buying an additional 5,450 shares in the last quarter. Hedge funds and other institutional investors own 99.23% of the company’s stock.

Get AMN Healthcare Services alerts:

Analyst Ratings Changes

A number of research analysts have weighed in on AMN shares. BMO Capital Markets reduced their price target on AMN Healthcare Services from $27.00 to $22.00 and set an “outperform” rating on the stock in a research note on Monday, August 11th. JMP Securities reduced their price target on AMN Healthcare Services from $33.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. Finally, UBS Group reduced their price target on AMN Healthcare Services from $30.00 to $25.50 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.25.

AMN Healthcare Services Trading Down 0.3%

AMN stock opened at $20.69 on Tuesday. The company has a market cap of $792.84 million, a price-to-earnings ratio of -2.66 and a beta of 0.10. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.51. The business has a fifty day simple moving average of $20.03 and a 200-day simple moving average of $21.51. AMN Healthcare Services Inc has a 52 week low of $14.86 and a 52 week high of $54.01.

AMN Healthcare Services (NYSE:AMN – Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.13. The business had revenue of $658.18 million during the quarter, compared to the consensus estimate of $652.89 million. AMN Healthcare Services had a positive return on equity of 11.09% and a negative net margin of 10.75%.The business’s revenue for the quarter was down 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.98 EPS. AMN Healthcare Services has set its Q3 2025 guidance at EPS. On average, equities research analysts expect that AMN Healthcare Services Inc will post 1.33 EPS for the current year.

AMN Healthcare Services Profile

(Free Report)

AMN Healthcare Services, Inc provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions.

Read More

Want to see what other hedge funds are holding AMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMN Healthcare Services Inc (NYSE:AMN – Free Report).

Receive News & Ratings for AMN Healthcare Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMN Healthcare Services and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/26/invesco-ltd-trims-stake-in-amn-healthcare-services-inc-amn/


[TITLE]Charles Schwab Investment Management Inc. Acquires 74,476 Shares of Healthcare Services Group, Inc. $HCSG:
[TEXT]
Charles Schwab Investment Management Inc. raised its holdings in Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report) by 8.4% in the 1st quarter, HoldingsChannel reports. The fund owned 965,843 shares of the business services provider’s stock after acquiring an additional 74,476 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Healthcare Services Group were worth $9,736,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Royce & Associates LP grew its stake in shares of Healthcare Services Group by 0.3% in the first quarter. Royce & Associates LP now owns 4,684,038 shares of the business services provider’s stock worth $47,215,000 after purchasing an additional 15,439 shares during the last quarter. Mackenzie Financial Corp raised its position in Healthcare Services Group by 0.8% during the 1st quarter. Mackenzie Financial Corp now owns 4,128,934 shares of the business services provider’s stock worth $41,620,000 after purchasing an additional 34,037 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Healthcare Services Group by 9.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,523,745 shares of the business services provider’s stock worth $29,313,000 after buying an additional 208,810 shares during the period. Palisade Capital Management LP grew its position in shares of Healthcare Services Group by 0.9% in the 1st quarter. Palisade Capital Management LP now owns 2,237,866 shares of the business services provider’s stock valued at $22,558,000 after buying an additional 20,720 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in shares of Healthcare Services Group by 12.5% in the 4th quarter. Janus Henderson Group PLC now owns 1,266,785 shares of the business services provider’s stock valued at $14,714,000 after buying an additional 140,708 shares during the last quarter. Institutional investors own 97.97% of the company’s stock.

Get Healthcare Services Group alerts:

Healthcare Services Group Stock Up 3.6%

Healthcare Services Group stock opened at $15.77 on Monday. The company has a market capitalization of $1.14 billion, a PE ratio of 112.64 and a beta of 0.54. Healthcare Services Group, Inc. has a 12-month low of $9.13 and a 12-month high of $15.80. The firm’s fifty day moving average is $14.28 and its 200 day moving average is $12.77.

Insider Buying and Selling

Healthcare Services Group ( NASDAQ:HCSG Get Free Report ) last posted its quarterly earnings results on Wednesday, July 23rd. The business services provider reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.01. Healthcare Services Group had a net margin of 0.61% and a return on equity of 11.74%. The firm had revenue of $458.50 million during the quarter, compared to the consensus estimate of $450.78 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The business’s revenue was up 7.6% compared to the same quarter last year. Healthcare Services Group has set its Q3 2025 guidance at EPS. Sell-side analysts expect that Healthcare Services Group, Inc. will post 0.74 EPS for the current fiscal year.

In related news, EVP John Christopher Shea sold 21,368 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $13.25, for a total transaction of $283,126.00. Following the transaction, the executive vice president directly owned 32,976 shares of the company’s stock, valued at approximately $436,932. This represents a 39.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is owned by insiders.

Analyst Ratings Changes

HCSG has been the subject of a number of analyst reports. Robert W. Baird raised their price objective on Healthcare Services Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Zacks Research raised shares of Healthcare Services Group to a “strong-buy” rating in a research report on Tuesday, August 12th. Wall Street Zen downgraded shares of Healthcare Services Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 26th. Benchmark upped their price objective on shares of Healthcare Services Group from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Finally, Macquarie raised shares of Healthcare Services Group from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $15.00 to $16.00 in a research note on Tuesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Healthcare Services Group has an average rating of “Buy” and an average target price of $16.25.

Get Our Latest Stock Report on HCSG

Healthcare Services Group Profile

(Free Report)

Healthcare Services Group, Inc provides management, administrative, and operating services to the housekeeping, laundry, linen, facility maintenance, and dietary service departments of nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States. It operates through two segments, Housekeeping and Dietary.

Read More

Want to see what other hedge funds are holding HCSG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report).

Receive News & Ratings for Healthcare Services Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthcare Services Group and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/25/charles-schwab-investment-management-inc-acquires-74476-shares-of-healthcare-services-group-inc-hcsg/


[TITLE]Nuveen LLC Acquires New Holdings in Healthcare Services Group, Inc. $HCSG:
[TEXT]
Nuveen LLC acquired a new stake in Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 1,165,133 shares of the business services provider’s stock, valued at approximately $11,745,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Trail Ridge Investment Advisors LLC lifted its stake in Healthcare Services Group by 4.7% in the 1st quarter. Trail Ridge Investment Advisors LLC now owns 23,233 shares of the business services provider’s stock valued at $234,000 after purchasing an additional 1,048 shares during the last quarter. SummerHaven Investment Management LLC lifted its stake in Healthcare Services Group by 1.8% in the 1st quarter. SummerHaven Investment Management LLC now owns 73,841 shares of the business services provider’s stock valued at $744,000 after purchasing an additional 1,297 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Healthcare Services Group by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,880 shares of the business services provider’s stock valued at $486,000 after acquiring an additional 1,461 shares during the period. North Star Investment Management Corp. increased its position in Healthcare Services Group by 1.8% in the 1st quarter. North Star Investment Management Corp. now owns 102,950 shares of the business services provider’s stock valued at $1,038,000 after acquiring an additional 1,850 shares during the period. Finally, Sterling Capital Management LLC increased its position in Healthcare Services Group by 803.4% in the 4th quarter. Sterling Capital Management LLC now owns 2,358 shares of the business services provider’s stock valued at $27,000 after acquiring an additional 2,097 shares during the period. Institutional investors own 97.97% of the company’s stock.

Get Healthcare Services Group alerts:

Healthcare Services Group Stock Up 3.6%

HCSG opened at $15.77 on Friday. Healthcare Services Group, Inc. has a twelve month low of $9.13 and a twelve month high of $15.80. The company has a fifty day moving average of $14.28 and a 200-day moving average of $12.75. The stock has a market cap of $1.14 billion, a PE ratio of 112.64 and a beta of 0.54.

Analyst Ratings Changes

Healthcare Services Group ( NASDAQ:HCSG Get Free Report ) last posted its quarterly earnings data on Wednesday, July 23rd. The business services provider reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.01. Healthcare Services Group had a net margin of 0.61% and a return on equity of 11.74%. The company had revenue of $458.50 million during the quarter, compared to analysts’ expectations of $450.78 million. During the same period in the prior year, the company posted $0.20 earnings per share. Healthcare Services Group’s revenue for the quarter was up 7.6% compared to the same quarter last year. Healthcare Services Group has set its Q3 2025 guidance at EPS. Sell-side analysts anticipate that Healthcare Services Group, Inc. will post 0.74 EPS for the current fiscal year.

Several equities analysts have issued reports on the stock. Benchmark upped their price target on shares of Healthcare Services Group from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Zacks Research upgraded shares of Healthcare Services Group to a “strong-buy” rating in a research report on Tuesday, August 12th. Robert W. Baird upped their price target on shares of Healthcare Services Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Macquarie upgraded shares of Healthcare Services Group from a “neutral” rating to an “outperform” rating and upped their price target for the company from $15.00 to $16.00 in a research report on Tuesday, July 29th. Finally, Wall Street Zen cut shares of Healthcare Services Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 26th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $16.25.

View Our Latest Analysis on HCSG

Insider Buying and Selling at Healthcare Services Group

In other news, EVP John Christopher Shea sold 21,368 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $13.25, for a total transaction of $283,126.00. Following the completion of the sale, the executive vice president directly owned 32,976 shares in the company, valued at $436,932. This represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.60% of the stock is currently owned by company insiders.

Healthcare Services Group Company Profile

(Free Report)

Healthcare Services Group, Inc provides management, administrative, and operating services to the housekeeping, laundry, linen, facility maintenance, and dietary service departments of nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States. It operates through two segments, Housekeeping and Dietary.

Further Reading

Want to see what other hedge funds are holding HCSG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report).

Receive News & Ratings for Healthcare Services Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthcare Services Group and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/23/nuveen-llc-acquires-new-holdings-in-healthcare-services-group-inc-hcsg/

================================================================================

[TITLE]AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline:
[TEXT]
NORTH CHICAGO, Ill. and NEW YORK, Aug. 25, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. ("Gilgamesh") today announced a definitive agreement under which AbbVie will acquire Gilgamesh's lead investigational candidate, currently in clinical development for the…

This story appeared on news.abbvie.com , 2025-08-25 14:52:27.963000.
[Source link]: https://biztoc.com/x/f90a0380efe821c8


[TITLE]American Century Companies Inc. Increases Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA:
[TEXT]
American Century Companies Inc. boosted its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) by 1.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 1,092,754 shares of the company’s stock after purchasing an additional 13,046 shares during the quarter. American Century Companies Inc.’s holdings in Centessa Pharmaceuticals were worth $15,714,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of CNTA. Janus Henderson Group PLC grew its position in Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after purchasing an additional 3,614,623 shares during the last quarter. Foresite Capital Management VI LLC purchased a new stake in Centessa Pharmaceuticals during the 4th quarter valued at
[Source link]: https://www.etfdailynews.com/2025/08/25/american-century-companies-inc-increases-stake-in-centessa-pharmaceuticals-plc-sponsored-adr-cnta/


[TITLE]Charles Schwab Investment Management Inc. Boosts Stock Position in Recursion Pharmaceuticals, Inc. $RXRX:
[TEXT]
Charles Schwab Investment Management Inc. lifted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 0.2% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 2,278,401 shares of the company’s stock after purchasing an additional 4,398 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Recursion Pharmaceuticals were worth $12,053,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Softbank Group CORP. acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $99,152,000. Novo Holdings A S purchased a new position in Recursion Pharmaceuticals in the fourth quarter valued at
[Source link]: https://www.etfdailynews.com/2025/08/25/charles-schwab-investment-management-inc-boosts-stock-position-in-recursion-pharmaceuticals-inc-rxrx/


[TITLE]HighTower Advisors LLC Invests $1.97 Million in Catalyst Pharmaceuticals, Inc. $CPRX:
[TEXT]
HighTower Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 81,340 shares of the biopharmaceutical company’s stock, valued at approximately $1,972,000.

Other large investors have also recently modified their holdings of the company. Park Square Financial Group LLC bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at approximately $29,000. Sound Income Strategies LLC bought a new position in shares of Catalyst Pharmaceuticals during the 1st quarter valued at approximately $64,000. GAMMA Investing LLC increased its position in shares of Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 579 shares during the last quarter. Quarry LP bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at approximately $104,000. Finally, PNC Financial Services Group Inc. increased its position in shares of Catalyst Pharmaceuticals by 57.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 2,002 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Get Catalyst Pharmaceuticals alerts:

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of the company’s stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the sale, the insider directly owned 41,081 shares in the company, valued at approximately $1,085,360.02. This represents a 3.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.40% of the company’s stock.

Wall Street Analyst Weigh In

CPRX has been the topic of several analyst reports. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 5th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Wall Street Zen downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 9th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $33.20.

Check Out Our Latest Stock Analysis on Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Stock Up 2.5%

Shares of Catalyst Pharmaceuticals stock opened at $21.08 on Friday. The stock’s fifty day moving average is $21.29 and its two-hundred day moving average is $22.60. The company has a market capitalization of $2.58 billion, a PE ratio of 12.78, a price-to-earnings-growth ratio of 0.86 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.00 and a 52 week high of $26.58.

Catalyst Pharmaceuticals Company Profile

(Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Further Reading

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report).

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/24/hightower-advisors-llc-invests-1-97-million-in-catalyst-pharmaceuticals-inc-cprx/

================================================================================

[TITLE]Brooklyn Investment Group Makes New Investment in Sana Biotechnology, Inc. $SANA:
[TEXT]
Brooklyn Investment Group purchased a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) during the first quarter, Holdings Channel.com reports. The firm purchased 25,943 shares of the company’s stock, valued at approximately $44,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of SANA. Geode Capital Management LLC boosted its holdings in shares of Sana Biotechnology by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock worth $5,206,000 after buying an additional 26,601 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Sana Biotechnology by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 62,021 shares of the company’s stock worth $101,000 after buying an additional 20,950 shares in the last quarter. Cerity Partners LLC bought a new position in shares of Sana Biotechnology during the 4th quarter worth approximately $25,000. Renaissance Technologies LLC boosted its holdings in shares of Sana Biotechnology by 1,838.3% during the 4th quarter. Renaissance Technologies LLC now owns 319,818 shares of the company’s stock worth $521,000 after buying an additional 303,318 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Sana Biotechnology during the 4th quarter worth approximately $152,000. 88.23% of the stock is currently owned by institutional investors.

Get Sana Biotechnology alerts:

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SANA. JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley began coverage on Sana Biotechnology in a report on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $8.00.

Sana Biotechnology Stock Down 0.6%

Shares of SANA opened at $3.58 on Friday. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.30. The business’s fifty day moving average is $3.64 and its 200 day moving average is $2.70. The stock has a market cap of $851.36 million, a P/E ratio of -3.38 and a beta of 1.90.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. On average, analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.
[Source link]: https://www.etfdailynews.com/2025/08/24/brooklyn-investment-group-makes-new-investment-in-sana-biotechnology-inc-sana/


[TITLE]Vanguard Group Inc. Reduces Stake in Vir Biotechnology, Inc. $VIR:
[TEXT]
Vanguard Group Inc. lessened its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 2.5% in the first quarter, Holdings Channel reports. The fund owned 12,807,508 shares of the company’s stock after selling 323,127 shares during the quarter. Vanguard Group Inc. owned
[Source link]: https://www.etfdailynews.com/2025/08/24/vanguard-group-inc-reduces-stake-in-vir-biotechnology-inc-vir/


[TITLE]Vir Biotechnology, Inc. $VIR Shares Acquired by Public Sector Pension Investment Board:
[TEXT]
Public Sector Pension Investment Board lifted its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 27.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 292,578 shares of the company’s stock after purchasing an additional 63,284 shares during the period. Public Sector Pension Investment Board’s holdings in Vir Biotechnology were worth $1,896,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. State of Tennessee Department of Treasury increased its position in shares of Vir Biotechnology by 3.2% during the fourth quarter. State of Tennessee Department of Treasury now owns 39,268 shares of the company’s stock worth $288,000 after purchasing an additional 1,227 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Vir Biotechnology by 26.2% during the first quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock worth $68,000 after purchasing an additional 2,171 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Vir Biotechnology by 0.6% during the fourth quarter. Invesco Ltd. now owns 398,772 shares of the company’s stock worth $2,927,000 after buying an additional 2,574 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Vir Biotechnology by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 38,290 shares of the company’s stock worth $248,000 after buying an additional 3,209 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Vir Biotechnology by 5.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 71,332 shares of the company’s stock worth $524,000 after buying an additional 3,506 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Get Vir Biotechnology alerts:

Wall Street Analyst Weigh In

A number of research firms recently issued reports on VIR. Raymond James Financial began coverage on Vir Biotechnology in a report on Friday, July 11th. They set an “outperform” rating on the stock. Needham & Company LLC reissued a “buy” rating and set a $14.00 price target on shares of Vir Biotechnology in a report on Thursday, May 22nd. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.25.

Vir Biotechnology Stock Performance

Shares of VIR opened at $4.36 on Thursday. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $14.45. The stock’s 50 day moving average is $5.16 and its two-hundred day moving average is $6.14. The firm has a market capitalization of $605.69 million, a PE ratio of -1.09 and a beta of 1.18.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.38 million. During the same period in the prior year, the firm posted ($1.02) EPS. Vir Biotechnology’s revenue for the quarter was down 60.5% compared to the same quarter last year. On average, sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Insider Buying and Selling

In other Vir Biotechnology news, EVP Mark Eisner sold 6,796 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $5.47, for a total value of $37,174.12. Following the sale, the executive vice president owned 108,204 shares of the company’s stock, valued at approximately $591,875.88. The trade was a 5.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 22,000 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $4.99, for a total value of $109,780.00. Following the sale, the director directly owned 1,276,391 shares in the company, valued at $6,369,191.09. This trade represents a 1.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 57,582 shares of company stock worth $294,930 in the last ninety days. 16.00% of the stock is owned by corporate insiders.

Vir Biotechnology Company Profile

(Free Report)

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

Read More

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report).

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/21/vir-biotechnology-inc-vir-shares-acquired-by-public-sector-pension-investment-board/

================================================================================

[TITLE]SCWorx Expands Healthcare Data Management Network with New Collaboration:
[TEXT]
Tampa, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) today announced a new agreement with a leading healthcare supply chain partner, further strengthening its SaaS data management program.

The partner is a recognized leader in healthcare supply chain consulting, with deep experience helping hospitals unlock cost savings and optimize spend management. The partner also has access to best-in-class products and services at the local, regional, and national levels for virtually every product or service to help hospitals optimize their direct and indirect procurement spend categories.

“This partner drives measurable savings by vetting vendors, analyzing contracts, and leveraging billions in spend through strategic purchasing. They have purchasing partners in all 50 states and are growing every day. All of this helps the partner anticipate, identify, and proactively deliver cost-saving opportunities through cooperative purchasing on an ongoing basis,” said Tim Hannibal, SCWorx CEO. Hannibal added, “The SCWorx Foundation product will help this partner enhance their product line and provide additional value to their healthcare customer. This partner chose SCWorx for its data cleanse, normalization and enrichment service offerings. SCWorx is a valuable data management service partner specifically built to help hospitals in the U.S. better utilize data. This partnership reinforces the unique value SCWorx delivers to hospitals nationwide.”
[Source link]: https://www.globenewswire.com/news-release/2025/08/26/3139426/0/en/SCWorx-Expands-Healthcare-Data-Management-Network-with-New-Collaboration.html


[TITLE]Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference:
[TEXT]
MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 8, 2025 (6:50 a.m. AEST, Sep 9) and at the H.C. Wainwright 27th Annual Global Investment Conference at 12:00 p.m. ET on Tuesday, September 9, 2025 (2:00 a.m. AEST, Sep 10).

Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in fireside chats at both conferences being held in New York (NY). Each session will be webcast live, and available on demand following the events.
[Source link]: https://www.globenewswire.com/news-release/2025/08/26/3139147/0/en/Telix-to-Present-at-the-Morgan-Stanley-23rd-Annual-Global-Healthcare-Conference-and-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html


[TITLE]Quantbot Technologies LP Invests $554,000 in Healthcare Services Group, Inc. $HCSG:
[TEXT]
Quantbot Technologies LP bought a new position in Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 54,967 shares of the business services provider’s stock, valued at approximately $554,000. Quantbot Technologies LP owned approximately 0.08% of Healthcare Services Group at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of HCSG. US Bancorp DE lifted its holdings in Healthcare Services Group by 161.4% during the 1st quarter. US Bancorp DE now owns 8,097 shares of the business services provider’s stock worth $82,000 after buying an additional 5,000 shares in the last quarter. PharVision Advisers LLC acquired a new position in Healthcare Services Group during the 4th quarter worth $147,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Healthcare Services Group by 45.3% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,592 shares of the business services provider’s stock worth $147,000 after buying an additional 4,548 shares in the last quarter. Dark Forest Capital Management LP acquired a new position in Healthcare Services Group during the 4th quarter worth $158,000. Finally, MQS Management LLC acquired a new position in Healthcare Services Group during the 1st quarter worth $173,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

Get Healthcare Services Group alerts:

Wall Street Analysts Forecast Growth

HCSG has been the topic of several research reports. Macquarie raised Healthcare Services Group from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, July 29th. Benchmark upped their price objective on Healthcare Services Group from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Wall Street Zen cut shares of Healthcare Services Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 26th. Robert W. Baird upped their target price on shares of Healthcare Services Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Finally, Zacks Research upgraded shares of Healthcare Services Group to a “strong-buy” rating in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Healthcare Services Group has an average rating of “Buy” and a consensus target price of $16.25.

Insider Buying and Selling

In related news, EVP John Christopher Shea sold 21,368 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $13.25, for a total transaction of $283,126.00. Following the sale, the executive vice president owned 32,976 shares of the company’s stock, valued at approximately $436,932. This trade represents a 39.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.10% of the company’s stock.

Healthcare Services Group Trading Down 1.8%

Shares of Healthcare Services Group stock opened at $15.49 on Tuesday. The company has a market capitalization of $1.12 billion, a PE ratio of 110.64 and a beta of 0.54. Healthcare Services Group, Inc. has a 12 month low of $9.13 and a 12 month high of $15.89. The stock’s fifty day simple moving average is $14.29 and its 200 day simple moving average is $12.81.

Healthcare Services Group (NASDAQ:HCSG – Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The business services provider reported $0.21 EPS for the quarter, topping the consensus estimate of $0.20 by $0.01. The business had revenue of $458.50 million for the quarter, compared to the consensus estimate of $450.78 million. Healthcare Services Group had a return on equity of 11.74% and a net margin of 0.61%.The firm’s revenue was up 7.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 EPS. Healthcare Services Group has set its Q3 2025 guidance at EPS. Analysts predict that Healthcare Services Group, Inc. will post 0.74 EPS for the current fiscal year.
[Source link]: https://www.etfdailynews.com/2025/08/26/quantbot-technologies-lp-invests-554000-in-healthcare-services-group-inc-hcsg/


[TITLE]Invesco Ltd. Trims Stake in AMN Healthcare Services Inc $AMN:
[TEXT]
Invesco Ltd. lowered its stake in AMN Healthcare Services Inc (NYSE:AMN – Free Report) by 10.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 348,521 shares of the company’s stock after selling 40,043 shares during the quarter. Invesco Ltd.’s holdings in AMN Healthcare Services were worth $8,525,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMN. Golden State Wealth Management LLC lifted its stake in AMN Healthcare Services by 107.0% in the 1st quarter. Golden State Wealth Management LLC now owns 1,159 shares of the company’s stock valued at $28,000 after buying an additional 599 shares in the last quarter. LRI Investments LLC lifted its stake in AMN Healthcare Services by 368.2% in the 4th quarter. LRI Investments LLC now owns 1,620 shares of the company’s stock valued at $39,000 after buying an additional 1,274 shares in the last quarter. Covestor Ltd lifted its stake in AMN Healthcare Services by 59.6% in the 1st quarter. Covestor Ltd now owns 4,650 shares of the company’s stock valued at $114,000 after buying an additional 1,736 shares in the last quarter. GAMMA Investing LLC lifted its stake in AMN Healthcare Services by 74.9% in the 1st quarter. GAMMA Investing LLC now owns 5,278 shares of the company’s stock valued at $129,000 after buying an additional 2,260 shares in the last quarter. Finally, NBC Securities Inc. lifted its stake in AMN Healthcare Services by 109,000.0% in the 1st quarter. NBC Securities Inc. now owns 5,455 shares of the company’s stock valued at $133,000 after buying an additional 5,450 shares in the last quarter. Hedge funds and other institutional investors own 99.23% of the company’s stock.

Get AMN Healthcare Services alerts:

Analyst Ratings Changes

A number of research analysts have weighed in on AMN shares. BMO Capital Markets reduced their price target on AMN Healthcare Services from $27.00 to $22.00 and set an “outperform” rating on the stock in a research note on Monday, August 11th. JMP Securities reduced their price target on AMN Healthcare Services from $33.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. Finally, UBS Group reduced their price target on AMN Healthcare Services from $30.00 to $25.50 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.25.

AMN Healthcare Services Trading Down 0.3%

AMN stock opened at $20.69 on Tuesday. The company has a market cap of $792.84 million, a price-to-earnings ratio of -2.66 and a beta of 0.10. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.51. The business has a fifty day simple moving average of $20.03 and a 200-day simple moving average of $21.51. AMN Healthcare Services Inc has a 52 week low of $14.86 and a 52 week high of $54.01.

AMN Healthcare Services (NYSE:AMN – Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.13. The business had revenue of $658.18 million during the quarter, compared to the consensus estimate of $652.89 million. AMN Healthcare Services had a positive return on equity of 11.09% and a negative net margin of 10.75%.The business’s revenue for the quarter was down 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.98 EPS. AMN Healthcare Services has set its Q3 2025 guidance at EPS. On average, equities research analysts expect that AMN Healthcare Services Inc will post 1.33 EPS for the current year.

AMN Healthcare Services Profile

(Free Report)

AMN Healthcare Services, Inc provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions.

Read More

Want to see what other hedge funds are holding AMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMN Healthcare Services Inc (NYSE:AMN – Free Report).

Receive News & Ratings for AMN Healthcare Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMN Healthcare Services and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/26/invesco-ltd-trims-stake-in-amn-healthcare-services-inc-amn/

================================================================================

